FEATURES OF THE DEVELOPMENT OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH CORONARY HEART DISEASE AFTER REVASCULARIZATION
Keywords:
percutaneous coronary intervention, acute coronary syndrome, cardiovascular events, revascularization.Abstract
Coronary heart disease is the leading cause of death worldwide. The World Health Organization (WHO) reported that coronary heart disease was responsible for approximately nine million deaths in 2016. Developed and developing countries show opposite trends in mortality due to CHD. In developed countries such as the United States and the United Kingdom, mortality rates due to coronary heart disease are declining. Coronary revascularization using PCI is an important therapeutic option in the treatment of patients with CAD, and its use has increased over time [13,16,20]. However, the study showed that PCI, in addition to optimal drug therapy in patients with severe ischemic left ventricular systolic dysfunction, did not lead to a reduction in the rate of death or hospitalization due to heart failure compared to optimal drug therapy alone [17,19]. Therefore, the above findings require further research to address the challenges and constraints faced by CHD patients and their caregivers, as well as the opportunity to discuss effective and cost-effective solutions for disease management.
References
Reddy YNV, Obokata M, Wiley B, et al. The haemodynamic basis of lung congestion during exercise in HFpEF. Eur Heart J. 2019;40(45):3721–3730. doi: 10.1093/eurheartj/ehz713.
Houstis NE, Eisman AS, Pappagianopoulos PP, et al. Exercise Intolerance in HFpEF: Diagnosing and Ranking Its Causes Using Personalized O2 Pathway Analysis. Circulation. 2018;137(2):148–161. doi: 10.1161/CIRCULATIONAHA.117.029058.
Hernandez GA, Lemor A, Blumer V, et al. Trends in Utilization and Outcomes of Pulmonary Artery Catheterization in PH With and Without Cardiogenic Shock. Journal of Cardiac Failure. 2019;25(5):364–371. doi: 10.1016/j.cardfail.2019.03.004.
Garan AR, Kanwar M, Thayer KL, et al. Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality. JACC Heart Fail. 2020;8(11):903–913. doi: 10.1016/j.jchf.2020.08.012.
Rossello X, Bueno H, Gil V, et al. Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. Circ Heart Fail. 2021;14(3):e007347. doi: 10.1161/CIRCHEARTFAILURE.120.007347.
Jentzer JC, Burstein B, Van Diepen S, et al. Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients. Circ Heart Fail. 2021;14(1):e007678. doi: 10.1161/CIRCHEARTFAILURE.120.007678.
Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock. Catheterization and Cardiovascular Interventions. 2019;94(1):29–37. doi: 10.1002/ccd.28329.
Thayer KL, Zweck E, Ayouty M, et al. Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic Shock. Circ Heart Fail. 2020;13(9):e007099. doi: 10.1161/CIRCHEARTFAILURE.120.007099
Lim HS. Cardiac Power Output Revisited. Circ Heart Fail. 2020;13(10):e007393. doi: 10.1161/CIRCHEARTFAILURE.120.007393.
Tongers J, Sieweke J-T, Kühn C, et al. Early Escalation of Mechanical Circulatory Support Stabilizes and Potentially Rescues Patients in Refractory Cardiogenic Shock. Circ Heart Fail. 2020;13(3):e005853. doi: 10.1161/CIRCHEARTFAILURE.118.005853.
Frankfurter C, Molinero M, Vishram-Nielsen JKK, et al. Predicting the Risk of Right Ventricular Failure in Patients Undergoing LVAD Implantation: A Systematic Review. Circ Heart Fail. 2020;13(10):e006994. doi: 10.1161/CIRCHEARTFAILURE.120.006994.
Morine KJ, Kiernan MS, Pham DT, Paruchuri V, Denofrio D, Kapur NK. Pulmonary Artery Pulsatility Index Is Associated With Right Ventricular Failure After LVAD Surgery. Journal of Cardiac Failure. 2016;22(2):110–116. doi: 10.1016/j.cardfail.2015.10.019.
Kang G, Ha R, Banerjee D. Pulmonary artery pulsatility index predicts right ventricular failure after LVAD implantation. J Heart Lung Transplant. 2016;35(1):67–73. doi: 10.1016/j.healun.2015.06.009.
Uriel N, Sayer G, Addetia K, et al. Hemodynamic Ramp Tests in Patients With LVADs. JACC Heart Fail. 2016;4(3):208–217. doi: 10.1016/j.jchf.2015.10.001.
Imamura T, Jeevanandam V, Kim G, et al. Optimal Hemodynamics During LVAD Support Are Associated With Reduced Readmission Rates. Circ Heart Fail. 2019;12(2):e005094. doi: 10.1161/CIRCHEARTFAILURE.118.005094.
Dridi NP, Vishram-Nielsen JKK, Gustafsson F. Exercise Tolerance in Patients Treated With a Durable LVAD: Importance of Myocardial Recovery. Journal of Cardiac Failure. 2021;27(4):486–493. doi: 10.1016/j.cardfail.2020.12.005.
Hsu S, Kambhampati S, Sciortino CM, Russell SD, Schulman SP. Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock. Am Heart J. 2018;199:181–191. doi: 10.1016/j.ahj.2017.11.016.
Borlaug BA. Evaluation and management of HFpEF. Nat Rev Cardiol. 2020;17(9):559–573. doi: 10.1038/s41569-020-0363-2.
Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and HFpEF: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):245–257. doi: 10.1016/j.jcmg.2018.12.034.
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of PH. Eur Respir J. 2019;53(1):1801913. doi: 10.1183/13993003.01913-2018.
Vanderpool RR, Saul M, Nouraie M, Gladwin MT, Simon MA. Association Between Hemodynamic Markers of PH and Outcomes in HFpEF. JAMA Cardiol. 2018;3(4):298–306. doi: 10.1001/jamacardio.2018.0128.
Ho JE, Zern EK, Lau ES, et al. Exercise PH Predicts Clinical Outcomes in Patients With Dyspnea on Effort. J Am Coll Cardiol. 2020;75(1):17–26. doi: 10.1016/j.jacc.2019.10.048.
Reddy YNV, Obokata M, Koepp KE, Egbe AC, Wiley B, Borlaug BA. The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in HFpEF. Circ Res. 2019;124(2):306–314. doi: 10.1161/CIRCRESAHA.118.313832.
Egbe AC, Miranda WR, Anderson JH, Borlaug BA. Hemodynamic and Clinical Implications of Impaired Pulmonary Vascular Reserve in the Fontan Circulation. J Am Coll Cardiol. 2020;76(23):2755–2763. doi: 10.1016/j.jacc.2020.10.003.
Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016;68(5):473–482. doi: 10.1016/j.jacc.2016.05.043.
Givertz MM, Fang JC, Sorajja P, et al. Executive Summary of the SCAI/HFSA Clinical Expert Consensus Document on the Use of Invasive Hemodynamics for the Diagnosis and Management of Cardiovascular Disease. Journal of Cardiac Failure. 2017;23(6):487–491. doi: 10.1016/j.cardfail.2017.04.013.
Vonk Noordegraaf A, Chin KM, Haddad F, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in PH: an update. Eur Respir J. 2019;53(1):1801900. doi: 10.1183/13993003.01900-2018.
Ташкенбаева Э. Н., Насырова З. А., Мирзаев Р. З. Стратификация хронической ишемической болезни сердца в зависимости от методов диагностики и пути их лечения //Journal of cardiorespiratory research. – 2020. – Т. 1. – №. 3. – С. 28-32.
Abdulloeva M., Nasyrova Z. RISK STRATIFICATION AND INTENSIVE CARE OF PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION IN CLINICAL PRACTICE //Collection of scientific papers «SCIENTIA». – 2023. – №. February 3, 2023; Chicago, USA. – С. 205-206.
НАСЫРОВА З. А., ТАШКеНБАеВА Э. Н. ВЛИЯНИЕ ГЕНОВ ПРОВОСПАЛИТЕЛЬНЫХ ЦИТОКИНОВ И ТРЕВОЖНО-ДЕПРЕССИВНОГО СИНДРОМА НА ПРОГРЕССИРОВАНИЕ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА //AXBOROTNOMASI. – С. 53.
Ташкенбаева Э. Н., Насырова З. А., Тоиров А. Э. Течение нестабильных вариантов стенокардии при полиморбидных состояниях //Colloquium-journal. – Голопристанський міськрайонний центр зайнятості Голопристанский районный центр занятости, 2019. – №. 27-3. – С. 45-49.
Mirzaev R. Z., Akbarovna N. Z., Shazeb A. M. Clinical and Genetic Features of Unstable Angina Pectoris Depending on Various Psychosocial Risk Factors //International Journal of Alternative and Contemporary Therapy. – 2024. – Т. 2. – №. 4. – С. 4-8.
